基于模拟的激活凝血时间向心肺旁路在抗脂综合征患者:两个病例报告
Yuki Kamikawa1, Yosuke Saito2, Hiromi Fujii1
1Department of Cardiovascular Surgery, Toda Chuo General Hospital, Saitama, Japan.
General thoracic and cardiovascular surgery cases
|November 28, 2025
概括
接受心脏手术的抗脂综合征 (APS) 患者需要个性化抗凝药. 术前激活凝血时间 (ACT) 模拟为标准监测提供了一种实用,安全的替代方案,特别是在没有先进设备的情况下.
科学领域:
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
- 麻醉学 麻醉学
背景情况:
- 抗脂综合征 (APS) 是一种与系统性红斑狼 (SLE) 相关的自身免疫性疾病,在心脏外科手术中提出了挑战.
- 由于狼抗凝剂,标准激活凝血时间 (ACT) 监测在APS中不可靠,并且先进的监测设备很少.
研究的目的:
- 评估个性化手术前ACT模拟用于指导心脏手术的APS患者抗凝治疗的实用性.
- 在资源有限的环境中,展示一种实用且易于获得的替代传统监测方案.
主要方法:
- 包括两名患有APS的女性患者,他们在心肺绕道 (CPB) 下接受了大动脉置换 (AVR).
- 使用患者血清和肝素进行了手术前ACT模拟,以确定个性化的手术内ACT目标.
- 手术后减少了对蛋白质胺的剂量.
主要成果:
- ACT模拟成功引导了抗凝药,使这两位患者能够安全地进行AVR和左心房附属器截肢.
- 两位患者都经历过渡性,经过手术后出血的良好控制,没有血栓性或重大出血并发症.
- 对相同度的肝素的个性化ACT反应突出了对个性化抗凝策略的需求.
结论:
- 个性化手术前ACT模拟是一种实用且易于使用的方法,用于在心脏手术期间在APS患者中管理抗凝剂.
- 这种技术提高了外科手术期间的安全性,特别是在缺乏先进监测设备的场所.
- 需要在更大的队列中进一步验证,以确认这种方法的有效性和安全性.
相关概念视频
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
281
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
281
Venous Thrombosis III: Interprofessional Care
265
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
265
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.0K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.0K


